Evaluation of the Pharmacokinetic Interaction of Ubrogepant Coadministered With Sumatriptan and of the Safety of Ubrogepant With Triptans.

CONCLUSIONS: Although there were slight alterations in ubrogepant pharmacokinetic parameters when coadministered with sumatriptan, such changes are expected to have minimal clinical relevance, especially because no changes were seen in sumatriptan area under the curve and maximum plasma concentration when coadministered with ubrogepant. Coadministration of ubrogepant with sumatriptan was well tolerated in healthy participants in the Phase 1 study, and coadministration of ubrogepant with triptans was well tolerated in participants with migraine in the Phase 3 trials. No new safety concerns for ubrogepant were identified across all trials. PMID: 32573795 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32573795?dopt=Abstract

Source: Headache - June 22, 2020 Category: Neurology Authors: Jakate A, Boinpally R, Butler M, Lu K, McGeeney D, Periclou A Tags: Headache Source Type: research